Natera, Inc. $NTRA Shares Purchased by Pallas Capital Advisors LLC

Key Points

• Pallas Capital Advisors LLC increased its holdings in Natera, Inc. by 28.6%, owning 12,320 shares valued at approximately $2.08 million as of the latest SEC filing.
• Several analysts have set strong price targets for Natera, with estimates ranging from $170.00 to $220.00, and a consensus target of $194.00, indicating a positive outlook for the stock.
• In recent transactions, insiders, including Solomon Moshkevich, sold significant shares, totaling over $8.45 million in value, indicating potential changes in confidence among company executives.

Pallas Capital Advisors LLC boosted its holdings in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 28.6% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 12,320 shares of the medical research company's stock after buying an additional 2,742 shares during the quarter. Pallas Capital Advisors LLC's holdings in Natera were worth $2,081,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in NTRA. HighPoint Advisor Group LLC lifted its stake in shares of Natera by 30.8% in the 1st quarter. HighPoint Advisor Group LLC now owns 1,986 shares of the medical research company's stock valued at $308,000 after acquiring an additional 468 shares during the last quarter. Amalgamated Bank raised its stake in Natera by 9.8% during the 1st quarter. Amalgamated Bank now owns 8,293 shares of the medical research company's stock worth $1,173,000 after buying an additional 740 shares during the period. Comerica Bank lifted its position in Natera by 24.1% in the 1st quarter. Comerica Bank now owns 141,106 shares of the medical research company's stock valued at $19,954,000 after acquiring an additional 27,379 shares in the last quarter. GAMMA Investing LLC lifted its position in Natera by 32.3% in the 1st quarter. GAMMA Investing LLC now owns 848 shares of the medical research company's stock valued at $120,000 after acquiring an additional 207 shares in the last quarter. Finally, Teza Capital Management LLC bought a new position in shares of Natera during the 4th quarter worth approximately $221,000. Institutional investors and hedge funds own 99.90% of the company's stock.

Natera Stock Performance

Shares of Natera stock traded up $1.25 during trading on Friday, hitting $181.11. 1,489,046 shares of the stock traded hands, compared to its average volume of 858,746. The stock has a market cap of $24.86 billion, a P/E ratio of -94.82 and a beta of 1.68. Natera, Inc. has a twelve month low of $117.27 and a twelve month high of $183.00. The company has a fifty day moving average price of $156.80 and a two-hundred day moving average price of $155.09.

Natera (NASDAQ:NTRA - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The medical research company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.14). Natera had a negative net margin of 12.89% and a negative return on equity of 22.22%. The firm had revenue of $546.60 million for the quarter, compared to analyst estimates of $476.84 million. During the same period last year, the company earned ($0.30) EPS. The company's revenue was up 32.2% compared to the same quarter last year. Natera has set its FY 2025 guidance at EPS. On average, equities research analysts expect that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Insider Buying and Selling at Natera

In other Natera news, CFO Michael Burkes Brophy sold 3,045 shares of the stock in a transaction on Tuesday, July 29th. The stock was sold at an average price of $137.40, for a total transaction of $418,383.00. Following the sale, the chief financial officer owned 65,430 shares in the company, valued at $8,990,082. This represents a 4.45% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Solomon Moshkevich sold 3,000 shares of the firm's stock in a transaction dated Tuesday, July 1st. The stock was sold at an average price of $166.77, for a total value of $500,310.00. Following the completion of the sale, the insider directly owned 130,205 shares in the company, valued at $21,714,287.85. The trade was a 2.25% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 56,423 shares of company stock valued at $8,459,656 in the last quarter. Insiders own 5.63% of the company's stock.

Analyst Ratings Changes

Several brokerages have commented on NTRA. Stephens reissued an "overweight" rating and issued a $183.00 price target on shares of Natera in a report on Friday, August 15th. Royal Bank Of Canada set a $268.00 target price on shares of Natera and gave the company an "outperform" rating in a research note on Tuesday, September 2nd. Cowen restated a "buy" rating on shares of Natera in a report on Friday, August 8th. Barclays restated an "overweight" rating and set a $210.00 target price (up previously from $190.00) on shares of Natera in a research note on Friday, August 8th. Finally, Piper Sandler reiterated an "overweight" rating and issued a $220.00 price target (up from $210.00) on shares of Natera in a report on Monday, August 11th. One investment analyst has rated the stock with a Strong Buy rating and seventeen have given a Buy rating to the stock. According to MarketBeat, the stock has an average rating of "Buy" and a consensus target price of $194.00.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.